PRESTRELSKI STEVEN
Known title: Chief Scientific OfficerCIK: 0001744027
Associated companies
Transaction History
| XERS | ▲ Buy | Grant | 150,000 | $0 | 1/31/2023 | View on chart |
| XERS | ▲ Buy | Option Exercise | 11,228 | $8K | 2/22/2022 | View on chart |
| XERS | ▼ Sell | Open Market | 11,228 | $27K | 2/22/2022 | View on chart |
| XERS | ▲ Buy | Grant | 75,000 | $0 | 1/3/2022 | View on chart |
| XERS | ▲ Buy | Grant | 384,780 | — | 10/5/2021 | View on chart |
| XERS | ▲ Buy | Grant | 110,000 | — | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit
Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit. Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.